- $641.23m
- $487.49m
Candel Therapeutics falls after announcing $100 mln stock offering, royalty agreement
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Candel Therapeutics Q3 net loss widens to $11.3 mln
Brief: Candel Therapeutics Q3 Net Income USD -11.269 Million
Brief: Candel Therapeutics Inc - Announces Encouraging Interim Data From CAN-3110 Trial
Brief: Candel Therapeutics Presents Phase 3 Clinical Trial Of Can-2409
Brief: Candel Therapeutics Extends Lease Term To Aug 31, 2029
Brief: Candel Therapeutics Q2 Net Income USD -4.796 Million
U.S. STOCKS ON THE MOVE-FedEx, Galaxy Digital, Cheniere Energy
Candel Therapeutics rises after $15 million direct stock deal
Brief: Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Brief: Candel Therapeutics Appoints Charles Schoch As Chief Financial Officer
Brief: Candel Therapeutics Q1 Net Income USD 7.379 Million
Brief: Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treatment
Brief: Candel Therapeutics Q4 Net Income USD -14.073 Million
U.S. STOCKS ON THE MOVE-Progressive Corp, Elf Beauty, ASP Isotopes
U.S. STOCKS ON THE MOVE-Canadian Solar, Quanex Building, PENN
U.S. STOCKS ON THE MOVE-Canadian Solar, Candel Therapeutics, Upstart Holdings
U.S. STOCKS ON THE MOVE-Boeing, Broadcom, RH